Irritable bowel syndrome. Relevance of antispasmodics

Luis M. Bustos-Fernández, MD.  

Abstract

Irritable bowel syndrome is a disorder characterized by abdominal pain related to changes in bowel movements. Despite the progress made in the knowledge of its pathophysiology and the emergence of new therapeutic forms, antispasmodics have remained over time as an effective way to treat symptoms, especially pain. The purpose of this review is to search for scientific evidence on the use of antispasmodics in the treatment of irritable bowel symptoms.

Keywords

Irritable bowel syndrome; Antispasmodic; Abdominal pain.

INTRODUCTION

Functional gastrointestinal disorders (FGID) are characterized by the appearance of predominant symptoms such as abdominal pain, bloating, distension or abnormal bowel habits (e.g. constipation, diarrhea, or both). FGIDs can be differentiated from other gastrointestinal disorders by their chronicity (6 months since symptom onset), current activity (symptoms within the last 3 months), frequency (symptoms, on average, at least 1 day per week), and the absence of obvious anatomical or physiological abnormalities identified through routine diagnostic tests, as deemed clinically appropriate (1).

FGIDs are classified into 5 different categories:

- Irritable bowel syndrome (IBS)
- Functional Constipation (FC)
- Functional Diarrhea (FD)
- Functional abdominal bloating (FAB)
- Unspecified annoyances

IBS is the most frequent of these diseases, with a prevalence of 11.2% worldwide. These data are based on a meta-analysis of 80 studies in which 260,960 subjects were evaluated. According to said study, IBS prevalence rates are higher in women than in men, while younger people are more likely to be affected by it than those over 50 (2).

In this context, IBS is a multifactorial disorder with a complex physiopathology. Factors that increase the risk of developing this syndrome may be genetic, environmental, or psychosocial, and aspects that trigger the onset or exacerbation of symptoms may include previous gastroenteritis, food intolerances and chronic stress (3).
Physiopathological mechanisms vary in each individual. They may include altered motility, visceral hyperalgesia, increased intestinal permeability, immune activation, altered microbiota, and alterations of the bowel-brain axis.

On the other hand, different psychological disorders have been associated with IBS (4, 5). The most frequent complaints are anxiety, depression, emotional vulnerability, and self-esteem disorders (6). In this sense, the treatment of IBS begins by providing the patient with information about the characteristics of the syndrome, reassuring them about the benign natural history of the condition, and educating them about the usefulness and safety of diagnostic tests.

Treatment is planned according to the type of symptoms and their severity. Lifestyle modifications can improve these symptoms. These changes include engaging in physical activity, reducing stress, and improving sleep quality (7). Different treatments have been proposed for the management of IBS, which are based on controlling its main symptoms.

- **Diarrhea:**
  - Opioid receptor agonists (loperamide) (8).
  - Diet (low in oligosaccharides, disaccharides, monosaccharides, and fermentable polyols, or FODMAP, and low in or gluten-free) (9-11).
  - Bile acid sequestrants (cholestyramine) (12).
  - Probiotics/antibiotics (rifaximin) (13-15).

- **Constipation:**
  - *Psyllium* (16).
  - Polyethylene glycol (PEG) (17).
  - Chlorine channel activators (*linaclotide*, lubiprostone) (18, 19).
  - Prokinetics (20).

- **Abdominal pain:**
  - Antispasmodics (*hyoscine butylbromide*) (16).
  - Smooth muscle regulators (21).
  - Tricyclic antidepressants (amitriptyline) (22).
  - Selective serotonin reuptake inhibitors (SSRIs) (paroxetine, escitalopram) (22).

- **Calcium channel blockers** (*pinaverium bromide*, oti-lonium bromide, alverine, fenoverine, rociverine and pyrenzepine).

Direct smooth muscle relaxants reduce muscle tone and peristalsis. In this way, they can relieve intestinal pain without substantially affecting gastrointestinal motility. On the other hand, anticholinergics attenuate spasms or contractions in the intestine and, therefore, have the potential to reduce abdominal pain (23, 24). Meanwhile, calcium antagonists relax the intestine by preventing calcium from entering intestinal smooth muscle cells. Since calcium triggers the cascade of events that triggers muscle contraction, its inhibition in the cells causes intestinal relaxation. This group of drugs can decrease the gastroduodenal reflex and modify bowel transit time by reducing the motility rate.

*Hyoscine N-butylbromide* is the most widespread antispasmodic on the market, both as an over-the-counter and as a prescription drug. It is marketed as a single drug or combined with painkillers. This is an alkaloid derived from belladonna, whose pharmacological properties are due to its anticholinergic effects, which make it effective to reduce the frequency and intensity of spasms in the gastrointestinal tract.

The ability of this drug to prevent motion sickness and vomiting is believed to be associated with vestibular inhibition in the central nervous system (CNS), which results in an inhibition of the vomit reflex. In addition, it has a direct action on the vomiting center, located in the reticular formation of the brain stem. This action makes it as an alternative to treat functional dyspepsia (25).

**ANTISPASMODICS IN IBS**

Different reviews and meta-analyses have been carried out to evaluate the management of IBS. In 2014, the American College of Gastroenterology published a review reporting that antispasmodics have been used for decades to treat IBS. This work was based on the concept that many of the symptoms of IBS are associated with intestinal smooth muscle spasms (16).

In said review, 25 controlled studies that evaluated 2154 patients were identified. Only three of these used standardized diagnostic criteria (Rome I, II) (26-28), while the other was conducted before the publication of the Rome criteria. This review shows that antispasmodic therapy has a statistically significant effect on the improvement of IBS symptoms, with a number needed to treat (NNT) of 5.

However, the effect of therapy with a single antispasmodic is variable and difficult to interpret, as there are only a small number of studies evaluating each of the 12 different drugs available for review. With respect to individual agents, oti-lonium bromide (26-28), hyoscine butylbromide (29-
Pinaverium bromide

Pinaverium bromide is also an antispasmodic calcium channel blocker used to treat IBS. It is usually administered alone or in combinations. In a meta-analysis conducted by Cochrane in 2011 that included 4 randomized clinical trials assessing the overall improvement of IBS symptoms in patients treated with this agent, statistically significant differences were found in the treatment group. In 3 of these randomized clinical trials, the efficacy of the drug to improve abdominal pain was also evaluated, finding significant differences in favor of pinaverium. Another meta-analysis published a year later, assessed the benefits of treatment of IBS based on the combination of pinaverium bromide and simethicone in two randomized clinical trials. One of them reported significant benefits of such combination regarding the improvement of abdominal distension, while the other one did not describe any advantages regarding overall improvement of symptoms and abdominal pain in comparison with the use of placebo.

Thus, both alone and in combination, otilonium bromide appears to be a safe drug, with adverse effects similar to those caused by placebo (21, 38).

Trimebutine maleate

Trimebutine maleate is another calcium channel blocker used to treat IBS. In high concentrations, this drug reduces the amplitude of spontaneous contractions and action potentials. It also has an analgesic effect and acts as a weak μ opioid receptor (MOR) agonist. A meta-analysis published in 2001 reported statistically significant differences in favor of trimebutine regarding overall symptom improvement. Meanwhile, another meta-analysis, previously cited in this review, describes significant advantages of using trimebutine for abdominal pain. However, studies assessing this drug have been carried out in a low number of patients, which explains why when including or excluding any publication from the analysis, the conclusions of the meta-analyses differ.

Regarding adverse effects, no differences versus placebo were reported in any of the publications included in this review (17-19).

Peppermint oil

Peppermint oil acts through several mechanisms: it is a calcium channel blocker, a κ–opioid receptor (KOR) antagonist, and a 5-HT3 antagonist. For this reason, besides having antispasmodic properties, it has other relevant effects on the treatment of IBS, such as the normalization of the orocecal transit time (40).
The available evidence on its use for treating IBS seems to be stronger than that of conventional antispasmodics. This is reported in a meta-analysis in which a significant improvement in abdominal pain and overall symptoms is observed, with an NNT of 4 and 3, respectively. Adverse effects such as nausea, vomiting, and heartburn were reported in this review. The latter seems to decrease when the drug is administered in three-layer tablets (40, 41).

**Eluxadoline**

Eluxadoline is a μ and κ opioid receptor agonist, as well as an δ-opioid receptor (DOR) antagonist in the enteric nervous system. The agonist action of MORs promotes delayed gastric emptying, slowed transit constipation, and increased anal sphincter pressure.

On the other hand, the effects of DORs antagonists counteract the resulting constipation and increase the analgesia of MOR agonism (42). Eluxadoline is indicated in the treatment of IBS cases with diarrhea and has shown NNTs ranging from 8 to 33, with average values of 12.5.

A meta-analysis on the use of Eluxadoline, conducted in 2017 and in which 2427 patients were included, showed a statistically significant improvement in abdominal pain relief, stool consistency, overall symptoms, and IBS-related quality of life.

However, significant adverse effects were also reported, including nausea, vomiting, abdominal pain, and constipation. A higher incidence of pancreatitis and spasm in the sphincter of Oddi was also found, particularly in patients who had previously undergone a cholecystectomy. Due to these events, the FDA (Food and Drug Administration) contraindicates the use of eluxadoline in people with a history of biliary disorders, pancreatitis, severe liver failure or alcoholism, as well as in individuals who have undergone cholecystectomy (42, 43).

**IBS TREATMENTS ACCORDING TO THE WGO**

In 2016, the World Gastroenterology Organisation (WGO) published the latest revision of the IBS guidelines, where issues regarding the treatment of this syndrome are addressed, and therapeutic options are proposed in accordance with the economic possibilities of the population (44).

**Low economic level**

- General measures: providing the patient with information, reassuring them, reviewing their diet and lifestyle.
- Symptomatic treatment:
  - Pain: antispasmodic available locally.
  - Constipation: dietary measures and fiber supplements.
  - Diarrhea: stool forming agents and loperamide

**Middle economic level**

- A quality probiotic with proven efficacy is added to the treatment mentioned above.

**High economic level**

- Psychiatric drugs, psychological treatments, consultations with specialized dietitians and specific pharmacological agents (lubiprostone, linaclotide, rifaximin) can be added.

These data make it clear that the group reviewing these guidelines proposes the use of the most locally available antispasmodics as the first line of treatment (44).

These guidelines propose a scheme to treat IBS, which includes a specific symptomatic treatment depending on the type and intensity of the symptom, as well as on the availability of the drug (Figure 1).

On the other hand, the guidelines of the American Gastroenterological Association (AGA) report a significant improvement in IBS symptoms when using antispasmodics. However, they point out that the use of these drugs is limited since most of them are not marketed in the United States (46).

In 2019, the latest meta-analysis assessing different therapies for the treatment of IBS was published. Soluble fiber, antispasmodic drugs and neuromodulators of the gut-brain axis were included. Regarding antispasmodics, it was concluded that the evidence supporting the use of peppermint oil is the most convincing and significant (46).

**CONCLUSIONS**

The treatment of IBS has different levels of complexity. With that in mind, antispasmodics continue to gain relevance in the management of this syndrome, supported by several scientific evidence. Beyond the fact that greater knowledge of the physiopathology of the disease has made it possible to find new therapeutic options, the use of these medications continues to be valid as a specific symptomatic treatment.
**IBS MANAGEMENT**

Exacerbation of symptoms

To calm down the patient, check the patient's diet and lifestyle

Long term

To use a probiotic with proven efficacy

Specific symptomatic treatment

To consider psychological approaches and make consultations with a dietitian

Specific symptomatic treatment

Exacerbation of symptoms

Figure 1. IBS treatment. IBS: Irritable bowel syndrome

**REFERENCES**


11. Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The Effect of Dietary Intervention on Irritable Bowel Syndrome:
31. Schäfer E, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol...

Review article


